益盛药业(002566) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥225,540,617.25, a decrease of 1.55% compared to ¥229,097,736.43 in the same period last year[4] - Net profit attributable to shareholders was ¥27,229,639.30, down 1.93% from ¥27,765,054.54 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥19,705,067.74, representing a decline of 15.81% from ¥23,405,772.17 in the previous year[4] - Total operating revenue for the current period is $225.54 million, a decrease of 1.23% from $229.10 million in the previous period[21] - Operating profit decreased to $33.67 million, down 19.73% from $41.91 million in the previous period[22] - Net profit for the current period is $29.23 million, a decline of 12.93% compared to $33.19 million in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 32.73% to ¥38,973,399.49, compared to ¥29,363,113.24 in the same period last year[4] - Cash flow from operating activities increased to $38.97 million, up 32.73% from $29.36 million in the previous period[26] - Cash and cash equivalents at the end of the quarter were CNY 200,989,827.14, down from CNY 219,695,016.40[17] - Cash and cash equivalents at the end of the period decreased to $200.99 million, down from $290.24 million in the previous period[27] - The company reported a net cash outflow from financing activities of $31.03 million, compared to an outflow of $12.24 million in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,850,618,838.70, a decrease of 0.48% from ¥2,864,366,655.13 at the end of the previous year[4] - The company's current assets totaled CNY 2,208,310,379.88, slightly down from CNY 2,221,792,551.02 at the start of the year[17] - The total liabilities decreased to CNY 650,352,779.13 from CNY 666,082,205.82[19] - The company's equity attributable to shareholders increased to CNY 2,109,039,378.83 from CNY 2,081,809,739.53[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,823[10] - Basic and diluted earnings per share decreased to $0.0823, down from $0.0839 in the previous period[23] Expenses - Total operating costs increased to $199.83 million, up 2.03% from $194.43 million in the previous period[21] - Financial expenses rose by 98.56% to ¥2,610,477.73, primarily due to decreased interest income and increased interest expenses[8] - Financial expenses increased to $2.61 million, up from $1.31 million in the previous period[22] - Research and development expenses for the current period were $4.34 million, a decrease of 10% from $4.82 million in the previous period[21] Government Support - The company received government subsidies amounting to ¥8,400,380.57 during the reporting period[6] Accounts Receivable and Inventory - The company's accounts receivable increased by 61.76% to ¥2,922,425.05, influenced by an increase in commercial acceptance bills[8] - Accounts receivable rose to CNY 223,010,062.92 from CNY 195,846,007.45, indicating a growth of approximately 13.8%[17] - Inventory levels were reported at CNY 1,593,579,012.74, a slight decrease from CNY 1,596,871,561.48[17] Other Information - The company is addressing issues related to shareholding transparency and has implemented a plan to rectify the situation regarding shareholding disclosures[13] - The company’s short-term borrowings remained stable at CNY 397,864,988.96, compared to CNY 397,862,867.43 at the beginning of the year[18] - The company’s net profit for the first quarter of 2022 is not explicitly stated in the provided documents, but the focus on product inclusion in COVID-19 treatment guidelines suggests potential revenue growth opportunities[14]